Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Hepa B Vaccine in Healthy Adults
NCT03627507Phase 3Completed
- Sponsor
- icddr,b
- Start
- Jul 2018
- Primary completion
- May 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Hepa-B in hepatitis B (HBV) (2 arms), sponsored by icddr,b. Primary endpoints: Seroprotection rate (percentage of participants with anti-HBs ≥10 mIU/ml) at 7 months, Number of immediate reactions and 3 more. Started Jul 2018; status: completed.
02
Drugs
Hepa-B
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03627507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627507.